Technical Analysis for ADPT - Adaptive Biotechnologies Corporation

Grade Last Price % Change Price Change
grade C 38.156 -1.28% -0.49
ADPT closed up 1.34 percent on Tuesday, July 16, 2019, on 17 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical ADPT trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.04%
Inside Day Range Contraction 0.04%
Hot IPO Pullback Bullish Swing Setup -2.16%
Outside Day Range Expansion -2.16%
Inside Day Range Contraction 1.37%
New 52 Week Closing Low Bearish 3.12%
Hot IPO Pullback Bullish Swing Setup 3.12%
New 52 Week Closing Low Bearish 1.72%
Hot IPO Pullback Bullish Swing Setup 1.72%
Multiple of Ten Bearish Other 1.72%

Older signals for ADPT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Cancer Diseases Infectious Diseases Cancers Drug Discovery Diagnostic Tests Leukemia
Is ADPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 0 bearish and 5 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 51.0
52 Week Low 36.21
Average Volume 1,388,385
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 38.42
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line -0.1569
MACD Signal Line -0.0483
MACD Histogram -0.1085
Fundamentals Value
Market Cap 4.65 Billion
Num Shares 120 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -264.73
Price-to-Sales 4.89
Price-to-Book 0.91
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.58
Resistance 3 (R3) 40.55 39.88 40.26
Resistance 2 (R2) 39.88 39.39 39.89 40.15
Resistance 1 (R1) 39.27 39.09 39.57 39.29 40.04
Pivot Point 38.59 38.59 38.75 38.61 38.59
Support 1 (S1) 37.98 38.10 38.29 38.01 37.26
Support 2 (S2) 37.31 37.80 37.32 37.15
Support 3 (S3) 36.69 37.31 37.04
Support 4 (S4) 36.72